Literature DB >> 19855420

Transplantation: time to rethink immunosuppression by mTOR inhibitors?

Marcus D Säemann, Giuseppe Remuzzi.   

Abstract

Several surprising findings indicate that pharmacological blocking of the multifunctional enzyme mTor fosters distinct differentiation programs in different immunocompetent cells. These data might lead to a striking change in our view of the role that mTor inhibition should have in immunosuppressive therapy for allogeneic transplant recipients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19855420     DOI： 10.1038/nrneph.2009.168

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  10 in total

1.  Reduced exposure to calcineurin inhibitors in renal transplantation.

Authors:  Henrik Ekberg; Helio Tedesco-Silva; Alper Demirbas; Stefan Vítko; Björn Nashan; Alp Gürkan; Raimund Margreiter; Christian Hugo; Josep M Grinyó; Ulrich Frei; Yves Vanrenterghem; Pierre Daloze; Philip F Halloran
Journal:  N Engl J Med       Date:  2007-12-20       Impact factor: 91.245

2.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.

Authors:  Greg M Delgoffe; Thomas P Kole; Yan Zheng; Paul E Zarek; Krystal L Matthews; Bo Xiao; Paul F Worley; Sara C Kozma; Jonathan D Powell
Journal:  Immunity       Date:  2009-06-19       Impact factor: 31.745

3.  Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.

Authors:  L Demopoulos; M Polinsky; G Steele; D Mines; M Blum; M Caulfield; A Adamkovic; Q Liu; M B Harler; C Hahn; A Singh
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

4.  Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.

Authors:  Piero Ruggenenti; Norberto Perico; Eliana Gotti; Paolo Cravedi; Vivette D'Agati; Elena Gagliardini; Mauro Abbate; Flavio Gaspari; Dario Cattaneo; Marina Noris; Federica Casiraghi; Marta Todeschini; Daniela Cugini; Sara Conti; Giuseppe Remuzzi
Journal:  Transplantation       Date:  2007-10-27       Impact factor: 4.939

5.  Enhancing CD8 T-cell memory by modulating fatty acid metabolism.

Authors:  Erika L Pearce; Matthew C Walsh; Pedro J Cejas; Gretchen M Harms; Hao Shen; Li-San Wang; Russell G Jones; Yongwon Choi
Journal:  Nature       Date:  2009-06-03       Impact factor: 49.962

Review 6.  Sirolimus early graft nephrotoxicity: clinical and experimental data.

Authors:  Nicolas Pallet; Eric Thervet; Christophe Legendre; Dany Anglicheau
Journal:  Curr Drug Saf       Date:  2006-05

7.  Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma.

Authors:  Patrizia Barozzi; Chiara Bonini; Leonardo Potenza; Michele Masetti; Gianni Cappelli; Paola Gruarin; Denise Whitby; Giorgio E Gerunda; Anna Mondino; Giovanni Riva; Daniela Vallerini; Chiara Quadrelli; Raffaella Bosco; Fabio Ciceri; Claudio Bordignon; Thomas F Schulz; Giuseppe Torelli; Mario Luppi
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

8.  The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Authors:  Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann
Journal:  Immunity       Date:  2008-10-09       Impact factor: 31.745

9.  Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells.

Authors:  Chinnaswamy Jagannath; Devin R Lindsey; Subramanian Dhandayuthapani; Yi Xu; Robert L Hunter; N Tony Eissa
Journal:  Nat Med       Date:  2009-03-01       Impact factor: 53.440

10.  mTOR regulates memory CD8 T-cell differentiation.

Authors:  Koichi Araki; Alexandra P Turner; Virginia Oliva Shaffer; Shivaprakash Gangappa; Susanne A Keller; Martin F Bachmann; Christian P Larsen; Rafi Ahmed
Journal:  Nature       Date:  2009-06-21       Impact factor: 49.962
  10 in total
  2 in total

1.  B cell-specific deficiencies in mTOR limit humoral immune responses.

Authors:  Shuling Zhang; Margaret Pruitt; Dena Tran; Wendy Du Bois; Ke Zhang; Rushi Patel; Shelley Hoover; R Mark Simpson; John Simmons; Joy Gary; Clifford M Snapper; Rafael Casellas; Beverly A Mock
Journal:  J Immunol       Date:  2013-07-15       Impact factor: 5.422

2.  Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells.

Authors:  C Macedo; H R Turnquist; M Castillo-Rama; A F Zahorchak; R Shapiro; A W Thomson; D Metes
Journal:  Am J Transplant       Date:  2013-08-22       Impact factor: 8.086
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.